SCHEMBL2701682

SCHEMBL2701682

COc1ccc2c(c1)c(CCN)c(C)n2C

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ADRB2 P07550 1/20 0.56
MAPT P10636 2/20 0.53
ALDH1A1 P00352 2/20 0.53
KDM4E B2RXH2 1/20 0.53
MEN1 O00255 1/20 0.53
HPGD P15428 1/20 0.53
HTT P42858 1/20 0.53
KMT2A Q03164 1/20 0.53
HSD17B10 Q99714 1/20 0.53
L3MBTL1 Q9Y468 1/20 0.53
HTR6 P50406 4/20 0.52
HTR1D P28221 2/20 0.52
GAA P10253 1/20 0.48
BCHE P06276 2/20 0.47
ACHE P22303 2/20 0.47
PLA2G2A P14555 3/20 0.46
NQO2 P16083 1/20 0.46
MTNR1A P48039 1/20 0.46
MTNR1B P49286 1/20 0.46
NPSR1 Q6W5P4 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23608115 0.90 ADRB2 (0.46) ADRB2MAPTALDH1A1KDM4EMEN1
SCHEMBL23608109 0.90 ADRB2 (0.46) ADRB2MAPTALDH1A1KDM4EMEN1
SCHEMBL18927402 0.85 KDM4E (0.53) MAPTALDH1A1KDM4EMEN1HPGD
SCHEMBL18927518 0.84 PLA2G2A (0.54) MAPTALDH1A1KDM4EMEN1HPGD
SCHEMBL23777834 0.82 POLB (0.62) ADRB2ALDH1A1KDM4EMEN1HTT
Fumaric Acid SCHEMBL23608110 0.81 PLA2G2A (0.42) ADRB2MAPTALDH1A1KDM4EMEN1
SCHEMBL6575542 0.81 HTR6 (0.48) ADRB2ALDH1A1HTR6PLA2G2AMTNR1B
SCHEMBL18271569 0.81 AKR1C3 (0.64) MAPTALDH1A1KDM4EMEN1HPGD
SCHEMBL10771285 0.80 PLA2G4A (0.40) ADRB2MAPTALDH1A1KDM4EHPGD
Hydrochloric Acid SCHEMBL6579614 0.80 HTR6 (0.48) ADRB2ALDH1A1HTR6MTNR1BNPSR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 118 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4704826-A1 COMPOSITIONS AND METHODS FOR TREATING POST-TRAUMATIC STRESS DISORDER Yale University (US) 2026-03-11 EP claimed
WO-2024226995-A1 COMPOSITIONS AND METHODS FOR TREATING POST-TRAUMATIC STRESS DISORDER YALE UNIVERSITY (US) 2024-10-31 WO claimed
CN-118234491-A Hallucinogen-fatty acid combinations 明德赛特制药公司 2024-06-21 CN claimed
EP-4351568-A1 HALLUCINOGEN-FATTY ACID COMBINATION Mindset Pharma Inc. (CA) 2024-04-17 EP claimed
EP-4346788-A2 ENANTIOMERIC ENTACTOGEN COMPOSITIONS AND METHODS OF THEIR USE Arcadia Medicine, Inc. (US) 2024-04-10 EP claimed
WO-2023177294-A1 TRANSMUCOSAL DELIVERY OF PSYCHOACTIVE COMPOUNDS PLETHORA THERAPEUTICS B.V. (NL) 2023-09-21 WO claimed
EP-4221682-A2 METHODS FOR DELIVERY OF PSYCHEDELIC MEDICATIONS BY INHALATION AND SYSTEMS FOR PERFORMING THE METHODS Cybin IRL Limited (IE) 2023-08-09 EP claimed
WO-2022256720-A2 ENANTIOMERIC ENTACTOGEN COMPOSITIONS AND METHODS OF THEIR USE ARCADIA MEDICINE, INC. (US) 2022-12-08 WO claimed
WO-2022069690-A2 METHODS FOR DELIVERY OF PSYCHEDELIC MEDICATIONS BY INHALATION AND SYSTEMS FOR PERFORMING THE METHODS CYBIN IRL LIMITED (IE) 2022-04-07 WO claimed
CN-113956188-A Synthesis method of N, N-dimethyl-5-methoxytryptamine 河北维达康生物科技有限公司 2022-01-21 CN claimed
WO-2017189528-A1 CORROSION INHIBITOR COMPOSITIONS AND METHODS OF USING SAME Ecolab USA, Inc. (US) 2017-11-02 WO claimed
US-20170306504-A1 CORROSION INHIBITOR COMPOSITIONS AND METHODS OF USING SAME CHAMPIONX LLC 2017-10-26 US claimed
CN-105636438-A Pharmaceutical composition comprising an AMPK activator and a serotonin active agent and uses thereof CHEN JIANHONG 2016-06-01 CN claimed
CN-103751943-A Fire extinguishing composition containing nitrogenous organic compound XI AN JIAN RUI SAFETY EMERGENCY EQUIPMENT LTD LIABILITY COMPANY 2014-04-30 CN claimed
US-20120108510-A1 METHODS OF IMPROVING BEHAVIORAL THERAPIES EMORY UNIVERSITY (US) 2012-05-03 US claimed
EP-2001877-A1 METHOD FOR EXTRACTING TARGET ALKALOID USING AN IONIC LIQUID AS EXTRACTING SOLVENT Bioniqs Limited (GB) 2008-12-17 EP claimed
WO-2007110637-A1 METHOD FOR EXTRACTING TARGET ALKALOID USING AN IONIC LIQUID AS EXTRACTING SOLVENT BIONIQS LIMITED (GB) 2007-10-04 WO claimed
US-12611417-B1 Compositions and methods to inhibit acid-catalyzed dephosphorylation of phosphoryloxytryptamines Convergent Health Sciences LLC: (US) 2026-04-28 US disclosed
US-4882331-A ANTIDEPRESSANTS LES LABORATOIRES MERAM (FR) 1989-11-21 US disclosed
EP-0288360-A1 Derivatives of 1-[(1,1-diphenyl)-1-alkenyl] piperazine, process for their preparation and compositions containing them Société anonyme: LES LABORATOIRES MERAM (FR) 1988-10-26 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12611417-B1 Compositions and methods to inhibit acid-catalyzed dephosphorylation of phosphoryloxytryptamines PLCB1, PHKG1, PLCB3 ADRB2 801/4885MAPT 2085/4885ALDH1A1 2191/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.